Exacerbation Risk and Health Care Resource use among patients with asthma using ICS+Tiotropium versus ICS/LABA

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/44102
• EU PAS number:
  EUPAS44101
• Study ID:
  44102
• Official title and acronym:
  Exacerbation Risk and Health Care Resource use among patients with asthma using ICS+Tiotropium versus ICS/LABA
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  To conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use LABA medication in combination with ICS.
• Study status:
  Ongoing

Research institutions and networks

Institutions

eMAX Health

Study timelines

Date when funding contract was signed

Planned: 04/08/2020

Actual: 04/08/2020

Study start date

Planned: 01/10/2015

Actual: 14/05/2021

Data analysis start date

Planned: 14/05/2021

Actual: 14/05/2021

Date of final study report

Planned: 23/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer-ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable